Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study

[1]  Daniel M. Alschuler,et al.  Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial , 2020, Psychological Medicine.

[2]  P. Fisher,et al.  Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol , 2020, Frontiers in Psychiatry.

[3]  G. Knudsen,et al.  Psychometric Properties of the Verbal Affective Memory Test-26 and Evaluation of Affective Biases in Major Depressive Disorder , 2020, Frontiers in Psychology.

[4]  B. Sahakian,et al.  Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study , 2020, Psychological Medicine.

[5]  C. Harmer,et al.  Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment , 2020, Psychopharmacology.

[6]  R. Elliott,et al.  Psychometric Properties and Validation of the EMOTICOM Test Battery in a Healthy Danish Population , 2019 .

[7]  R. Shelton,et al.  Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial , 2019, BMC Psychiatry.

[8]  T. Karagiannis,et al.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression , 2019, Molecular Biology Reports.

[9]  M. Semkovska,et al.  Cognitive function following a major depressive episode: a systematic review and meta-analysis. , 2019, The lancet. Psychiatry.

[10]  G. Dawson,et al.  Predicting treatment response to antidepressant medication using early changes in emotional processing , 2019, European Neuropsychopharmacology.

[11]  K. Douglas,et al.  A Systematic Review of Cognitive Predictors of Treatment Outcome in Major Depression , 2018, Front. Psychiatry.

[12]  R. McIntyre,et al.  Predicting antidepressant response using early changes in cognition: A systematic review , 2018, Behavioural Brain Research.

[13]  S. Crowe,et al.  A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples , 2018, Neuropsychology Review.

[14]  B. Sahakian,et al.  Cognition as a treatment target in depression , 2016, Psychological Medicine.

[15]  P. Cowen,et al.  Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression , 2016, Translational psychiatry.

[16]  L. Williams,et al.  Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. , 2016, The lancet. Psychiatry.

[17]  P. Bech,et al.  Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D₆) as outcome measure. , 2016, Journal of affective disorders.

[18]  A Malizia,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines , 2015, Journal of psychopharmacology.

[19]  Leanne M Williams,et al.  A Cognitive–Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial , 2015, Neuropsychopharmacology.

[20]  K. Miskowiak,et al.  'Hot' cognition in major depressive disorder: a systematic review. , 2015, CNS & neurological disorders drug targets.

[21]  R. McIntyre,et al.  A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults , 2014, The international journal of neuropsychopharmacology.

[22]  J. Roiser,et al.  Cognitive impairment in depression: a systematic review and meta-analysis , 2013, Psychological Medicine.

[23]  Paul Kudlow,et al.  COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS , 2013, Depression and anxiety.

[24]  P. Cowen,et al.  ‘It's the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[25]  E. Bora,et al.  Cognitive impairment in euthymic major depressive disorder: a meta-analysis , 2012, Psychological Medicine.

[26]  M. Poo,et al.  Grand challenges in global mental health , 2011, Nature.

[27]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[28]  M. J. Knight,et al.  Cognitive dysfunction in major depressive disorder , 2018, Current opinion in psychiatry.

[29]  R. Elliott,et al.  Cognitive Mechanisms of Treatment in Depression , 2012, Neuropsychopharmacology.

[30]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[31]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .